978 resultados para 7-63
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Resumo:
The present study aimed to evaluate the efficacy of fipronil (1 mg/kg) against three strains of ivermectin-resistant Rhipicephalus (Boophilus) microplus (R. (B.) microplus), naturally infesting cattle from different states of Brazil. Three rural properties with a history of macrocyclic lactones ineffectiveness against the cattle tick, and low frequency use of fipronil in the herd, were selected for the study. The animals were randomized according to the mean tick counts, performed on days 3, 2 and I, into three groups with 10 animals each: T01, control (saline solution); T02, subcutaneous ivermectin (0.63 mg/kg) and T03, topical fipronil (1 mg/kg). Treatment was performed on day 0. Counts of partially engorged female ticks were performed on days 3,7 and 14 post-treatment (DPT), and then every 7 days until the 49th DPT. In all three experiments, it was possible to diagnose resistance of R. (B.) microplus to ivermectin (0.63 mg/kg). The maximum efficacy (arithmetic mean) obtained for ivermectin was 64% in experiment II. On the other hand, the formulation containing fipronil (1 mg/kg) reached high efficacy values (>= 97%) in all three experiments. The results from all experiments in this study demonstrate the high efficacy of 1 mg/kg fipronil, administered pour-on in naturally infested cattle, against strains of R. (B.) microplus that are resistant to 630 mcg/kg ivermectin. (C) 2014 Elsevier B.V. All rights reserved.
Resumo:
The long-term efficacy and safety of intravenous abatacept in patients (pts) with juvenile idiopathic arthritis (JIA) have been reported previously from the Phase III AWAKEN trial ([1, 2]). Here, we report efficacy, safety and pt-reported outcomes from the open-label, long-term extension (LTE) of AWAKEN, with up to 7 years of follow-up. Pts entered the LTE if they were JIA ACR 30 non-responders (NR) at the end of the 4-month lead-in period (abatacept only), or if they received abatacept or placebo (pbo) in the 6-month double-blind (DB) period. The Child Health Questionnaire was used to evaluate health-related quality of life (HRQoL); physical (PhS) and psychosocial (PsS) summary and pain scores were analyzed. Pain was assessed by parent global assessment using a 100 mm visual analog scale. Efficacy and HRQoL evaluations are reported up to Day 1765 (~ Year 5.5). Safety is presented for the cumulative period (lead-in, DB and LTE), for all pts who received abatacept during the LTE. Of the 153 pts entering the LTE (58 from DB abatacept group, 59 from DB pbo group, 36 NR), 69 completed the trial (29 abatacept, 27 pbo, 13 NR). For pts treated in the LTE, mean (range) exposure to abatacept was 53.6 (5.6–85.6) months. During the LTE, incidence rates of AEs and serious AEs per 100 pt-years were 209.1 and 5.6. Thirty pts (19.6%) had serious AEs; most were unrelated and were musculoskeletal (8.5%) or infectious events (6.5%). No malignancy was reported. There was one death (accidental; unrelated). At Day 169, JIA ACR 50 and 70 response rates were 79.3% and 55.2% in the abatacept group, and 52.5% and 30.5% in the pbo group; 31.0% and 10.2% of pts in the abatacept and pbo groups, respectively, had inactive disease. By Day 1765, JIA ACR 50 and 70 response rates were 93.9% and 78.8% in the abatacept group, and 80.0% and 63.3% in the pbo group; 51.5% and 33.3% had inactive disease. In the NR group, 69.2% and 53.8% of pts achieved JIA ACR 50 and 70 responses at Day 1765, and 30.8% had inactive disease. In pts who entered the LTE, mean baseline PhS scores were below the range for healthy children (abatacept 30.2, pbo 31.0, NR 29.5). At Day 169, 38.3% of pts had reached a PhS score >50 ((1). By the end of the LTE, 43.5% of pts had reached a PhS score >50. At baseline, mean PsS scores for those who entered the LTE were slightly lower than the mean for healthy children (abatacept 43.5, pbo 44.2, NR 47.0). At Day 169, 54.9% of pts had a PsS score >50 (1). By Day 1765, 58.1% of pts had reached a PsS score >50. At baseline, the mean pain score was 42.9. By Day 169, 13.9% of pts were considered pain free (pain score = 0); this was maintained over the LTE (1).
Resumo:
A convenient synthesis of new 5,6,7 ,8-tetrahydro-imidazo[ 1,2-a]pyrimidin-2-ones and 3,4,6,7 ,8,9-hexahydro-pyrimido[1 ,2a]pyrimidin-2- ones from the Baylis-Hillman adducts of acrylonitrile and their derivatives is described. A common strategy employed to achieve the syntheses of title compounds involved generation of diamines from different Baylis-Hillman derivatives followed by treatment with cyanogen bromide at reflux temperature to trigger a double intramolecular cyclization.
Resumo:
von J. Hirschfeld
Resumo:
Vortrag von Josef Eschelbacher
Resumo:
"Der neueste Angriff auf die Metaphysik" (GS 4, S. 108-161), veröffentlicht in: Zeitschrift für Sozialforschung VI, 1937, S. 4-53, englische Fassung mit dem Titel "The latest Attack on Metaphysics", Typoskript mit handschriftlichen Korrekturen, 63 Blatt; "Bemerkungen zu Jaspers' 'Nietzsche'" (GS 4, S. 226-235), veröffentlicht in: Zeitschrift für Sozialforschung VI, 1937, S. 407-414, Typoskript mit eigenhändigen Korrekturen, 8 Blatt;
Resumo:
Grossmann, Henrik: "The Nature of Economic Crisis". Typoskript, 4 Blatt; Über die Tätigkeiten des Institutes für Sozialforschung. Verschiedene Berichte. 1940- 1941; "Report to the Trustees of the Kurt Gerlach Memorial Foundation". 25.01.1940, Typoskript, 5 Blatt; "Manuskript under preparation". Januar 1940, handschriftliche Liste, 1 Blatt; Horkheimer, Max: "Über die allgemeine Lage des Instituts". Bericht für das Advisory Bord (New York members) Meeting, 22.04.1940; sowie ein Protokoll des Treffens, Typoskript, 5 Blatt; "Annual Report on the Activities of the Société International de Recherces Sociales, Presented to the Eight General Meeting in New York City on April 27, 1940"; sowie "Report on the Activities of the International Institute of Social Research for the Year 1939". Typoskript, 13 Blatt; "Report to the Trustees of the Kurt Gerlach Memorial Foundation". 23.02.1941, Typoskript mit eigenhändigen Ergänzungen von Max Horkheimer und handschriftlichen Ergänzungen und Korrekturen von Leo Löwenthal, 7 Blatt; Liste der Veröffentlichungen und der Forschungsgebiete des Instituts für Sozialforschung; "Content of Periodicals. List of Articles and Selected Major Book Reviews Arranged According to Contibutors. List of Articles and Selected Major Book Reviews Arranged According Topics. 1934-1941". a) Typoskript, 14 Blatt; b) Typoskript , 15 Blatt; "Literatur über features". 03.02.1941, Veröffentlichungsliste, 1 Blatt; Veröffentlichungsliste zu den Gebieten Nationalsozialismus, Massenkultur, Sozialgeschichte des späteren Mittelalters; 19.12.1941, Typoskript, 1 Blatt; Ankündigung und Übersicht über die ersten Nummern der "Studies in Philosophy and Social Science". 1941; Typoskripte und Drucksachen, 3 Blatt; "Supplementary Memorandum on the Activities of the Institute from 1939 to 1941. (supplemented to December, 1942)". 1942, als Typoskript vervielfältigt, 5 Blatt; Über Organisation und Mitarbeiter des Institutes für Sozialforschung. 1943; a) Typoskript, 6 Blatt; b) Typoskript, 7 Blatt; c) Teilstück, Typoskript mit handschriftlichen Korrekturen, 2 Blatt; d) Teilstück, Typoskript, 3 Blatt; e) Entwurf, Typoskript mit handschriftlichen Korrekturen, 8 Blatt; "Annual Report on the Activities of the Social Studies Association, Inc.". 15.05.1943, Typoskript, 6 Blatt; "Statement of Prof. Dr. Max Horkheimer, Director of the Institut of Social Research on June 9, 1943. Reponse: Certain Charges made against the Institut of Social Research (Columbia University)". 1943; a) Typoskript, 6 Blatt; b) Typoskript mit handschriftlichen Randbemerkungen, 6 Blatt; c) deutsche Rückübersetzung, 1969, Typoskript mit handschriftlichen Korrekturen, 4 Blatt;